Business Context and Reporting Period
This Form 8-K Current Report was filed by CRISPR Therapeutics AG on October 14, 2021. The filing discloses significant changes to the company's executive leadership, specifically the appointment of a new Chief Financial Officer and the retirement of the incumbent.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
- New CFO Annual Salary: $435,000
- Target Bonus: 40% of base salary
- One-Time Signing Payment: $75,000 (subject to forfeiture if employment ends before November 14, 2022)
- Equity Grants: 90,000 stock options and 15,000 restricted stock units (RSUs)
Material Changes
The primary material change reported is the transition of the Chief Financial Officer role:
- Appointment: Brendan Smith was appointed Senior Vice President and Chief Financial Officer, effective October 14, 2021. He will also serve as the principal financial and accounting officer.
- Retirement: Michael Tomsicek retired from his position as Senior Vice President and Chief Financial Officer on October 14, 2021. The filing explicitly states this retirement is not the result of any disagreement regarding financial reporting or accounting policies.
- Transition: Mr. Tomsicek is expected to remain employed until on or before December 31, 2021, during which his unvested options will continue to vest.
Outlook, Risks, and Unusual Items
The filing details specific compensation risks and contingencies associated with the new CFO's employment agreement:
- Termination Provisions: In the event of termination without Cause or resignation for Good Reason, Mr. Smith is entitled to a six-month notice period with continued compensation and vesting. If such termination occurs within 12 months of a Change in Control, the notice period extends to 12 months, and all equity awards vest immediately.
- Administrative Leave: During the notice period, Mr. Smith may engage in other employment or consulting arrangements provided they do not interfere with his obligations to the Company.
- Forfeiture Risk: The $75,000 one-time payment is subject to forfeiture if employment is terminated for any reason prior to November 14, 2022.
Investor Verification Checklist
- Verify the vesting schedule details for the 90,000 stock options and 15,000 RSUs granted to Brendan Smith.
- Confirm the exact end date of Michael Tomsicek's employment to ensure a smooth transition of financial reporting responsibilities.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "Cause" and "Good Reason."
- Monitor future filings for any impact on the company's cash burn rate due to the new executive compensation package.